Zachary A Kohutek1, Emily S Weg1, Xin Pei1, Weiji Shi2, Zhigang Zhang2, Marisa A Kollmeier1, Michael J Zelefsky3. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: zelefskm@mskcc.org.
Abstract
OBJECTIVE: To characterize the impact of androgen-deprivation therapy (ADT) on the incidence of cardiovascular events (CE) in prostate cancer patients treated with radiotherapy (RT). MATERIALS AND METHODS: There were 2211 patients with localized prostate cancer treated with RT from 1988 to 2008 at our institution. There were 991 patients (44.8%) who received ADT at the time of RT for a median of 6.1 months. Salvage ADT was initiated prior to CE in 365 men (16.5%) at a median of 5.5 years (range: 0.6 to 18.4 years) after RT and continued for a median of 4.3 years. A nomogram was constructed to predict the 10-year risk of CE "post-RT" (i.e., after RT). RESULTS: Patients receiving ADT at the time of RT exhibited significantly higher 10-year incidence of CE (19.6%, 95% CI 17.0%-22.6%) than those not receiving ADT (14.3%, 95% CI 12.2%-16.7%, P = .005). On multivariate analysis, both ADT at the time of RT (P = .007) and the time of salvage (P = .0004) were associated with increased CE risk, as were advanced age (P = .02), smoking (P = .0007), history of diabetes (P = .0007), and history of CE before RT (P < .0001). A nomogram using patient age, smoking status, history of pre-RT CE, history of diabetes, and ADT use at the time of RT predicted the rate of 10-year CE with a C-index of 0.81 (95% CI, 0.72-0.88). CONCLUSION: While ADT is often an essential part of prostate cancer treatment, patients should be counseled regarding increased risks of CE and prophylactic efforts should be considered to mitigate that risk.
OBJECTIVE: To characterize the impact of androgen-deprivation therapy (ADT) on the incidence of cardiovascular events (CE) in prostate cancerpatients treated with radiotherapy (RT). MATERIALS AND METHODS: There were 2211 patients with localized prostate cancer treated with RT from 1988 to 2008 at our institution. There were 991 patients (44.8%) who received ADT at the time of RT for a median of 6.1 months. Salvage ADT was initiated prior to CE in 365 men (16.5%) at a median of 5.5 years (range: 0.6 to 18.4 years) after RT and continued for a median of 4.3 years. A nomogram was constructed to predict the 10-year risk of CE "post-RT" (i.e., after RT). RESULTS:Patients receiving ADT at the time of RT exhibited significantly higher 10-year incidence of CE (19.6%, 95% CI 17.0%-22.6%) than those not receiving ADT (14.3%, 95% CI 12.2%-16.7%, P = .005). On multivariate analysis, both ADT at the time of RT (P = .007) and the time of salvage (P = .0004) were associated with increased CE risk, as were advanced age (P = .02), smoking (P = .0007), history of diabetes (P = .0007), and history of CE before RT (P < .0001). A nomogram using patient age, smoking status, history of pre-RT CE, history of diabetes, and ADT use at the time of RT predicted the rate of 10-year CE with a C-index of 0.81 (95% CI, 0.72-0.88). CONCLUSION: While ADT is often an essential part of prostate cancer treatment, patients should be counseled regarding increased risks of CE and prophylactic efforts should be considered to mitigate that risk.
Authors: Daniel E Spratt; Zachary S Zumsteg; Pirus Ghadjar; Marisa A Kollmeier; Xin Pei; Gilad Cohen; William Polkinghorn; Yoshiya Yamada; Michael J Zelefsky Journal: BJU Int Date: 2014-01-22 Impact factor: 5.588
Authors: James W Denham; Allison Steigler; David S Lamb; David Joseph; Sandra Turner; John Matthews; Chris Atkinson; John North; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Catherine D'Este Journal: Lancet Oncol Date: 2011-05 Impact factor: 41.316
Authors: Mieke Van Hemelrijck; Hans Garmo; Lars Holmberg; Erik Ingelsson; Ola Bratt; Anna Bill-Axelson; Mats Lambe; Pär Stattin; Jan Adolfsson Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544
Authors: Glenn N Levine; Anthony V D'Amico; Peter Berger; Peter E Clark; Robert H Eckel; Nancy L Keating; Richard V Milani; Arthur I Sagalowsky; Matthew R Smith; Neil Zakai Journal: Circulation Date: 2010-02-01 Impact factor: 29.690
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith Journal: Eur Urol Date: 2008-01-15 Impact factor: 20.096
Authors: Victor Srougi; Jose Bessa; Mohammed Baghdadi; Igor Nunes-Silva; Jose Batista da Costa; Silvia Garcia-Barreras; Eric Barret; Francois Rozet; Marc Galiano; Rafael Sanchez-Salas; Xavier Cathelineau Journal: World J Urol Date: 2017-02-27 Impact factor: 4.226